8-K: ESS Tech Faces NYSE Delisting, Moves to OTC Trading

ESS Tech, Inc. has been notified by the NYSE of its intent to delist the company's common stock due to failure to meet continued listing standards, leading to an immediate trading suspension and a transition to the over-the-counter market.

Summary

• ESS Tech, Inc. received notification from the New York Stock Exchange (NYSE) on October 2, 2026, that trading of its common stock has been suspended immediately.
• The NYSE has initiated proceedings to delist the company's common stock due to its failure to maintain an average global market capitalization of at least $15 million over a consecutive 30-trading-day period, as required by Section 802.01B of the NYSE Listed Company Manual.
• This delisting action is separate from a previous determination on September 24, 2026, to commence delisting proceedings under Section 802.02 of the NYSE Listed Company Manual.
• The company anticipates its common stock will be quoted and traded on the over-the-counter (OTC) market under the ticker symbol GWHT.
• ESS Tech intends to request a review of the NYSE's determination by a Committee of the Board of Directors of the NYSE within ten business days.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the immediate suspension of trading and commencement of delisting proceedings by the NYSE, indicating severe financial distress and a loss of market confidence.

Positives

• The company remains an SEC reporting company and will continue to file annual, quarterly, and current reports.
• ESS Tech intends to pursue strategic transaction opportunities on an expedited basis to address market capitalization issues and potentially regain listed status.

Negatives

• Immediate suspension of trading on the NYSE.
• Commencement of proceedings to delist the company's common stock from the NYSE.
• The transition to the over-the-counter market will result in a significantly more limited and less liquid market for the common stock.
• Potential for further depression of the trading price of the common stock due to reduced liquidity.
• Uncertainty regarding whether broker-dealers will continue to provide public quotes on the OTC market or if trading volume will be sufficient for an efficient market.

Risks

• Risks arising from the suspension of trading and delisting of the company's common stock on the NYSE.
• Risks related to trading on the over-the-counter market, including reduced liquidity and potential further declines in stock price.
• The company's ability to conclude a strategic transaction or business combination.
• The company's ability to appeal the NYSE's determination.
• Potential for continued failure to meet NYSE continued listing standards.

Future Outlook

The company intends to request a review of the NYSE's delisting determination and is actively pursuing strategic transaction opportunities to address market capitalization issues and potentially regain listed company status. Trading is expected to continue on the over-the-counter market.

Management Comments

• "Our focus remains on the pursuit of all strategic transaction opportunities on an expedited basis that would address the market capitalization issues and enable continuation of the listed company."
• Statement by Drew Buckley, Chief Executive Officer of ESS.

Industry Context

StockSavvy.ai notes that delisting from a major exchange like the NYSE due to insufficient market capitalization is a severe indicator of market distress and a significant loss of investor confidence, often signaling deeper financial or operational challenges within the company. Transitioning to the OTC market typically results in reduced liquidity and investor scrutiny.

Stakeholder Impact

• Shareholders will experience significantly reduced market liquidity for their shares.
• Shareholders may face further declines in the trading price of their investment.
• Potential investors may be deterred by the reduced liquidity and the move to the OTC market.

Next Steps

• The Company intends to request a review of the NYSE's determination by a Committee of the Board of Directors of the NYSE.
• The Company will continue to file annual, quarterly, and current reports with the SEC.
• The Company will focus on pursuing strategic transaction opportunities.

Key Dates

Recommendation

The immediate suspension of trading and commencement of delisting proceedings by the NYSE due to failure to meet minimum market capitalization requirements are critical negative indicators. The transition to the OTC market signifies a severe loss of market confidence and liquidity, making it highly probable that the stock price will continue to decline. The company's stated focus on strategic transactions offers a slim possibility of recovery, but the current situation warrants a sell recommendation.

Keywords

delisting, NYSE, over-the-counter, market capitalization, listing standards, trading suspension, strategic transaction